title: Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience.
abstract: We retrospectively analysed the factors that influenced rate of haemopoietic recovery (HR) in 243 patients after transplantation with chemotherapy-mobilised autologous peripheral blood progenitor cells (PBPC). Approximately half the patients also received haemopoietic growth factors (HGF) for mobilisation. Conditioning for transplantation was with either chemotherapy alone or chemotherapy plus total body irradiation (TBI). Median time to recovery of granulocytes > or = 0.5 x 10(9)/l was 13 days (range 7-93 days) and of platelets > or = 50 x 10(9)/l 14 days (7-440). Speed of HR was greater, both for neutrophils and platelets for patients who received more rather than less CFU-GM than our median value of 18.9 x 10(4)/kg (P < 0.0001 in both instances) and more rather than less CD34-positive cells than our median value of 8.8 x 10(6)/kg (P < 0.0001 and P < 0.0005, respectively). For granulocyte recovery, in the multivariate analysis the dose of infused CFU-GM (P = 0.05) and the use of HGF for both mobilisation and post-transplantation (P < 0.0014) were significant positive factors. For platelet recovery in the multivariate analysis the dose of infused CFU-GM (P < 0.0016) was a positive factor. The use of busulphan and of TBI were significant adverse factors for rate of platelet recovery (P = 0.005 and 0.0004, respectively). When compared with non-HGF-mobilised PBPC, HGF-mobilised PBPC reduced the number of days of hospitalisation (28 vs 24, P = 0.0001) and of treatment with intravenous antibiotics (15 vs 11, P = 0.0004). These findings emphasise the importance of cell dose in accelerating haemopoietic recovery after autologous blood stem cell transplantation.
authors.affiliation: Laboratoire de Greffe de Moelle, UMR 5540, Université Victor Segaleu Bordeaux 2, France.
authors.forename: R M
authors.initials: RM
authors.lastname: Lowenthal
authors.forename: C
authors.initials: C
authors.lastname: Fabères
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: J M
authors.initials: JM
authors.lastname: Boiron
authors.forename: P
authors.initials: P
authors.lastname: Cony-Makhoul
authors.forename: A
authors.initials: A
authors.lastname: Pigneux
authors.forename: P
authors.initials: P
authors.lastname: Agape
authors.forename: G
authors.initials: G
authors.lastname: Vezon
authors.forename: R
authors.initials: R
authors.lastname: Bouzgarou
authors.forename: B
authors.initials: B
authors.lastname: Dazey
authors.forename: D
authors.initials: D
authors.lastname: Fizet
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: F
authors.initials: F
authors.lastname: Lacombe
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D019337:Hematologic Neoplasms / Q000097:blood / Q000628:therapy*; D006410:Hematopoiesis; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D016896:Treatment Outcome